Liberty Broadband (NASDAQ:LBRDP) Stock, Quote.Headers.trade-ideas

Liberty Broadband

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential and small to medium businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.

Liberty Broadband Corporation - Series A Cumulative Redeemable Preferred Stock

Liberty Broadband Corp

Morgan Stanley analyst David Arcaro maintains DTE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>) with a Overweight and raises the price target from $121 to $128.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on DTE Energy, Raises Price Target to $128

2seventy bio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>)&nbsp;and its partner Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma&nbsp;(idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone for newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41020153/2seventy-bio-provides-update-on-karmma-9-study-and-previews-anticipated-strong-third-quarter-reven" rel="noreferrer noopener">stem cell transplant</a>.
"Consistent with our focus on capital allocation and creating value for all stakeholders, we anticipate this decision will conserve over $80 million in near-term expenditures and accelerate our path to breakeven in 2025," said Chip Baird, CEO of 2seventy bio.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38114915/fda-approves-bristol-myers2seventy-bios-abecma-for-earlier-use-in-pretreated-blood-cancer-patient" rel="noreferrer noopener">FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer</a>.
2seventy also reported continued positive momentum in&nbsp;Abecma's expected return to growth in the earlier line setting following the FDA's approval in April 2024.
The company expects third-quarter&nbsp;Abecma&nbsp;U.S. revenue growth of approximately 30%&nbsp;from second-quarter revenue of $54 million. Demand, as measured by new patients undergoing apheresis in the third quarter, is also expected to reflect double-digit growth compared to the second quarter of 2024.
William Blair says while expectations for Abecma are generally low for investors at this point, the ability to maximize the opportunity in the current label would offset concerns about the fixed costs of the cell therapy franchise.
2seventy bio and BMS share equally in all profits and losses related to the development, manufacturing, and commercialization of&nbsp;Abecma&nbsp;in the U.S.
Overall, the announcement suggests moving CAR-T therapies into the earliest lines of treatment may have headwinds given the strong current standard of care. Therefore, we think thoughtful trial designs that reflect the changing standard of care will have the greatest potential of maximizing the CAR-T total addressable market."
Recently, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) acquired the Hemophilia A program and rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39532373/novo-nordisk-buys-2seventys-hemophilia-a-program-divestiture-supports-exclusive-focus-on-abecma" rel="noreferrer noopener">cells for autoimmune disease</a>.
2seventy bio will focus exclusively on the commercialization and continued development of&nbsp;Abecma.
Price Action: TSVT stock is down 7.65% at $4.41, and BMY stock is down 2.90% at $49.47 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41028246/flutter-bets-big-on-us-and-global-expansion-21b-revenue-goal-and-5b-buyback-in-sight" target="_blank" rel="noreferrer noopener">Flutter Bets Big On US And Global Expansion: $21B Revenue Goal And $5B Buyback In Sight</a>.</li>
</ul>

Analyst Color

Biotech

Health Care

Movers

Trading Ideas

General

TSVT

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 50 points on Wednesday.
The Dow traded down 0.35% to 42,060.13 while the NASDAQ rose 0.39% to 18,145.24. The S&amp;P 500 also rose, gaining, 0.06% to 5,736.28.
Check This Out: <a href="https://www.benzinga.com/news/24/09/41022196/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-with-over-4-dividend-yield">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Information technology shares jumped by 0.9% on Wednesday.
In trading on Wednesday, energy shares fell by 1.1%.
Top Headline
Sales of new single-family houses in the U.S. fell by 4.7% from the prior month to an annualized rate of 716,000 in August, compared to a revised 10.3% gain in July.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares shot up 20% to $ 10.87. Maxim Group and Oppenheimer increased price targets on the stock.</li>
<li>Shares of Eightco Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTO#NASDAQ">OCTO</a>) got a boost, surging 66% to $4.14. Eightco Holdings expects to deliver revenues of $100 million for 2025.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares were also up, gaining 20% to $0.1122 after the company announced it secured $1.25 million in financing and requested an FDA type A meeting to address the clinical hold on CER-1236.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vertex Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTNR#NASDAQ">VTNR</a>) shares dropped 65% to $0.1272 after the company announced it filed for Chapter 11 bankruptcy.</li>
<li>Shares of Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) were down 35% to $2.4401 after the company reported worse-than-expected fourth-quarter EPS results.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) was down, falling 18% to $7.71 after the company announced that the Company&#8217;s Board of Directors has determined to disband the Special Committee.</li>
</ul>
Commodities In commodity news, oil traded down 1.4% to $70.57 while gold traded up 0.5% at $2,689.20.
Silver traded up 0.1% to $32.43 on Wednesday, while copper rose 0.5% to $4.5120.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.20%, Germany's DAX fell 0.54% and France's CAC 40 fell 0.66%. Spain's IBEX 35 Index fell 0.31%, while London's FTSE 100 fell 0.22%.
Producer prices in Spain declined by 1.3% year-over-year in August compared to a revised 1.6% decline in the previous month. The consumer confidence indicator in France climbed to 95.1 in September from 92.5 in the prior month.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 falling 0.19%, Hong Kong's Hang Seng Index jumping 0.68%, China's Shanghai Composite Index gaining 1.16% and India's BSE Sensex gaining 0.30%.
The People's Bank of China cut its one-year policy loan rate by 30bps to 2.0%.
Economics
<ul>
<li>U.S. building permits increased by 4.6% to an annual rate of 1.470 million in August.</li>
<li>U.S. mortgage applications rose by 11% from the prior week during the week ending Sept. 20, compared to a 14.2% increase in the previous week.</li>
<li>Sales of new single-family houses in the U.S. fell by 4.7% from the prior month to an annualized rate of 716,000 in August of 2024, compared to a revised 10.3% gain in the prior month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/41021427/accenture-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurat">Accenture Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Markets

CAPR

CERO

OCTO

SFIX

VTNR

Crude Oil Down Over 1%; Stitch Fix Shares Plummet

Morgan Stanley analyst David Arcaro maintains CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) with a Equal-Weight and raises the price target from $30 to $32.

Morgan Stanley Maintains Equal-Weight on CenterPoint Energy, Raises Price Target to $32

Barclays analyst Ryan Macwilliams maintains Smartsheet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) with a Equal-Weight and raises the price target from $50 to $56.5.

SMAR

Barclays Maintains Equal-Weight on Smartsheet, Raises Price Target to $56.5

Morgan Stanley analyst Stephen Byrd maintains CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) with a Equal-Weight and raises the price target from $63 to $68.

Morgan Stanley Maintains Equal-Weight on CMS Energy, Raises Price Target to $68

Barclays analyst Duffy Fischer maintains NL Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NL#NYSE">NL</a>) with a Underweight and raises the price target from $5 to $6.

Barclays Maintains Underweight on NL Industries, Raises Price Target to $6

Morgan Stanley analyst Stephen Byrd maintains Atmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>) with a Overweight and raises the price target from $128 to $140.

Morgan Stanley Maintains Overweight on Atmos Energy, Raises Price Target to $140

Edgewise Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ewtx#NASDAQ">EWTX</a>) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials. The news is important because hypertrophic cardiomyopathy or HCM for short, is the leading cause of sudden cardiac-related death in people under 35.&nbsp;
HCM is a genetic disease causing thickening in the heart muscle, an industry worth more than $1.25 billion today and growing. There are no current treatments of this caliber, with doctors relying heavily on beta-blockers and lifestyle changes. If approved, it will rocket this company from obscurity into the ranks of blockbuster treatments like GLP-1 blockers, which are revolutionizing weight control.
&quot;There continues to be an unmet need for patients with obstructive and non-obstructive HCM, and we are excited to be part of the ongoing CIRRUS-HCM trial evaluating a novel treatment,&quot; commented Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Associate Professor of Medicine, University of Pennsylvania and CIRRUS-HCM Investigator.
<h2>Sell-Side Interest Points to Higher Prices for Edgewise Therapeutics&nbsp;</h2>
After years of wallowing, Edgewise Therapeutics&#39;s share price action began to perk up this year as the news stream turned positive and sell-side interest was reinvigorated. The trend of price target reductions ended, and now the revisions are leading the market higher.&nbsp;
The consensus estimate reported by Marketbeat.com assumes at least a 15% upside from the $28 level, but revisions lead to the high-end range. Wedbush is among the few issuing revisions immediately after the news was released, raising its target by 42% to $44 and just shy of the high of $48. That was set by Piper Sandler earlier this year and implies a 70% upside is possible for this healthcare stock within the next twelve months.&nbsp;
Institutional activity is also bullish for this market. The institutional activity is robustly in favor of higher prices, surging to a record in Q2 and sustaining a solid pace in Q3. The takeaway is that institutions, private equity, and venture capital own about 90% of this stock and insiders another 4.5%, showing a high conviction in their support.&nbsp;
<h2>Short-Squeeze in Edgewise Therapeutics Means Volatility Ahead</h2>
Short interest is a factor in the share price surge. The short interest was nearly 15% in the last report and sufficient for a squeeze. Because EDG-700 is still in early trials and far from approval, the company is far from revenue and profits, and the short-sellers will likely reposition at a higher level and weigh on the market over the next few quarters. The good news is that volatility and short-sellers mean the share price will likely decline to retest for solid support. In that scenario, the stock could retreat to the $22 level or lower, opening a more attractive entry for investors.&nbsp;
<h2>Edgewise is Not a One-Trick Pony</h2>
Edgewise Therapeutics has an attractive, if small, pipeline of candidates in early stage 1 and stage 2 trials. They target individuals with Duchenne and Becker muscular dystrophy and have shown positive results to date. The next batch of results from these tests is expected in Q4 of this year and may provide another catalyst for the market. Regarding operations, the company reports losses due to its research and lack of revenue, but the losses are manageable, given the balance sheet. The company has over half a billion in cash, sufficient to sustain operations at recent levels for over 15 quarters.&nbsp;
The price chart of EWTX looks good. The market is recovering from its post-IPO blahs and appears to be in a full reversal. The price action is supported by increasingly high volume, so it has a high probability of continuing its advance. However, Investors should expect resistance to cap gains near the all-time highs until further developments are announced.
<img alt="EWTX stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20240919123339_chart-ewtx-9192024.png" style="height:426px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/edgewise-therapeutics-soars-50-key-reasons-behind-the-surge/">Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge</a>&quot; first appeared on MarketBeat.

Mid Cap

Short Sellers

Insider Trades

IPOs

EWTX

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Morgan Stanley analyst Stephen Byrd maintains American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Overweight and raises the price target from $102 to $108.

Morgan Stanley Maintains Overweight on American Electric Power, Raises Price Target to $108

Barclays analyst Matthew Bouley maintains KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) with a Overweight and raises the price target from $78 to $99.

Barclays Maintains Overweight on KB Home, Raises Price Target to $99

DoorDash, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) stock surged Wednesday after KeyBanc analyst Justin Patterson upgraded the stock from Sector Weight to Overweight with a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/DASH/analyst-ratings" rel="noreferrer noopener">$177&nbsp;price target</a>.
Patterson noted DoorDash as a clear share gainer in a secular growth category with emerging revenue streams from advertising and new verticals like grocery.
When Patterson initiated DoorDash before <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40116158/doordash-q2-earnings-revenue-beat-eps-miss-total-orders-up-19-results-reflect-years-of-investment-a'" rel="noreferrer noopener">second-quarter earnings</a>, he was constructive on DoorDash&#8217;s fundamentals and long-term opportunity but cautious on near-term consumer spending data points, particularly around restaurants.
The analyst told DoorDash&#8217;s second-quarter results eased many concerns about any significant impact from weaker consumer spending. Additionally, a broader set of reports showed resilience, and he left the second quarter viewing consumer softness as more localized than widespread.
His latest survey results reinforced that DoorDash is still distancing peers in food delivery and showing early signs of success with grocery.
In turn, the analyst noted that consensus is understating both Gross Order Volume (GOV) and EBITDA growth in 2025E (he is 2% and 3% above consensus) and 2026E (he is 3% and 6% above consensus). Rolling forward a 20 times Enterprise Value to EBITDA valuation to 2026E, Patterson reached a price target of $177.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/41025133/doordash-stock-is-moving-higher-wednesday-whats-going-on" rel="noreferrer noopener">DoorDash Stock Is Moving Higher Wednesday: What&#8217;s Going On?</a>
After reviewing Patterson&#8217;s third-quarter Mobility and Delivery Survey and model assumptions, he became more confident that DoorDash is gaining ground in its core and emerging verticals. This should sustain over 15% GOV growth and drive EBITDA of $3.5 billion by 2026E (~6% above consensus).
Patterson&#8217;s latest survey showed ongoing gains in food delivery usage, with 39% using DoorDash the most, 23 points above Uber Technologies, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), and in grocery, 8% using DoorDash the most, up by 300 bps since December 2023.
The analyst noted a strong core and ramp in new verticals should support his revised estimates for ~17% and 15% GOV growth in 2025E and 2026E (versus consensus of 15% and 13%) and EBITDA of $2.6 billion and $3.5 billion (3% and 6% above consensus).
Price Action: DASH stock is up 1.27% at $143.48 at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40150236/doordash-and-exact-sciences-are-among-top-10-large-cap-gainers-last-week-july-28-aug-3-are-the-other" target="_blank" rel="noreferrer noopener">DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?</a></li>
</ul>
Photo courtesy: Shutterstock

Upgrades

Tech

DASH

UBER

DoorDash Positioned As Clear Market Share Gainer With Growth In Grocery And Ads, Analyst Says, Upgrades Stock

Morgan Stanley analyst Stephen Byrd maintains Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Equal-Weight and raises the price target from $81 to $85.

Morgan Stanley Maintains Equal-Weight on Ameren, Raises Price Target to $85

USW Says We Disagree With Result Of Board Of Arbitration's Decision Over Grievances Against U.S. Steel; "Nippon's Commitment To Our Facilities And Jobs Remains Uncertain As Ever"

Barclays analyst Trevor Young maintains GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) with a Overweight and raises the price target from $165 to $185.

GDDY

Barclays Maintains Overweight on GoDaddy, Raises Price Target to $185

Opentrons, a Long Island City-based biotech company, is at the forefront of the robot revolution. Known for its cutting-edge AI-powered robots, Opentrons is revolutionizing scientific research, particularly in health care. Backed by prominent investors like Bill Gates, the company is dramatically reducing costs in the biotech space by automating complex lab procedures, making science more accessible and efficient.
Don't Miss:
<ul>
<li>Don&#8217;t miss the real AI boom &#8211;<a href="https://www.benzinga.com/money/fundrise-innovation-fund"> here&#8217;s how to use just $10 to invest in high growth private tech companies.</a></li>
<li>Unlock a $400 billion opportunity by investing in the future of EV infrastructure on<a href="https://www.benzinga.com/money/dunamis-1"> this startup already valued at $50 million with just $500</a>.</li>
</ul>
Bill Gates has long been an advocate for global health initiatives. He donates heavily to fund <a href="https://www.benzinga.com/personal-finance/24/08/40667041/bill-gates-100m-alzheimers-research-support-his-visit-to-iu-school-of-medicine-and-how-he-recomm">Alzheimer's research</a> and the Bill and Melinda Gates Foundation also heads the <a href="https://www.benzinga.com/personal-finance/24/09/40794858/bill-gates-efforts-to-eradicate-malaria-and-the-economic-impact-of-ridding-the-globe-of-this-dis">fight against malaria</a> to eradicate the disease. So, it's no surprise that Gates is backing this innovative tech company.&nbsp;
Gates' involvement with Opentrons takes them one step closer to fulfilling their mission to make advanced technology accessible to scientists worldwide. According to the New York Post, Gates helped connect the company to rural African villages that needed the tech devices.&nbsp;
Trending: Teens may never need wisdom teeth removed thanks to this MedTech Company –<a href="https://www.benzinga.com/money/triagenics"> Be an early investor for just $300 for 100 shares!</a>
Jonathan Brennan-Badal, Opentrons' CEO, shared Gates' vision during an interview with The Post, saying, "His principle interest really is around how we can be building a platform and ecosystem … enabling third-party developers like other startups, scientists to build new applications for our robot, build new devices, hardware devices that can integrate with our platform."
Opentrons has integrated AI tools like <a href="https://www.benzinga.com/news/24/09/40890661/chatgpt-parent-openai-establishes-oversight-committee-for-safety-amid-recent-fears-of-biological-wea">ChatGPT</a> and large language models (LLM) into their robots to simplify the programming process. This allows scientists to use simple prompts, like "run a COVID test," without requiring extensive coding knowledge to get the robot to work. Once the prompt is said, the robot takes care of the rest.&nbsp;
These robots are saving scientists time and money worldwide. They are already deployed in 14 of the 15 leading global pharmaceutical companies, performing tasks such as sequencing DNA and intricate lab tests. They are transforming how scientists conduct their research.&nbsp;
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
On the topic of saving money, Opentrons' robots played a significant role during the COVID-19 pandemic. The company set up a Pandemic Response Lab (PRL) in 2020 and used 40 of its robots to conduct over 12 million COVID tests in New York City. This automation saved the city and taxpayers roughly 80% of the cost, approximating around $600 billion in savings. These robots were also the first to identify new variants of COVID-19, including Omicron.&nbsp;
Beyond the cost savings to taxpayers and scientists, the price point for Opentrons robots is also appealing. The robots start at $10,000, significantly more affordable than leading competitors, who charge around $100,000.&nbsp;
Trending: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
A more affordable robot like this allows smaller labs and research facilities to access this advanced technology worldwide. Opentrons' mission goes beyond just making a more affordable solution though. It's important that their robots are portable too. Their robots have been used in remote locations – and can even run on car batteries – to test for disease outbreaks.&nbsp;
Opentrons' innovation doesn't stop at testing. The company is working on reducing the astronomical costs of gene therapy, which currently exceeds $1 million per treatment. By leveraging <a href="https://www.benzinga.com/content/40971485/robotics-industry-growth-brings-new-jobs-and-housing-market-demand-to-colorado">robotics</a> and automation, Opentrons aims to reduce these costs to $30,000 or less, making lifesaving treatments accessible to a broader population.
Read Next:
<ul>
<li>Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Startups

Bill Gates Backs NYC's Robot Revolution: Opentrons AI Changing Science And Medicine With Robot Pricing Starting At $10,000

Financial giants have made a conspicuous bullish move on AST SpaceMobile. Our analysis of options history for AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) revealed 24 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $1,468,076, and 13 were calls, valued at $534,208.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $35.0 for AST SpaceMobile over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AST SpaceMobile's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AST SpaceMobile's substantial trades, within a strike price spectrum from $10.0 to $35.0 over the preceding 30 days.
<h3>AST SpaceMobile Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727279132_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.47</td>
<td>$22.50</td>
<td>$547.3K</td>
<td style="text-align: right;">128</td>
<td>2.4K</td>
</tr>
<tr>
<td>ASTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.48</td>
<td>$22.50</td>
<td>$411.6K</td>
<td style="text-align: right;">128</td>
<td>1.4K</td>
</tr>
<tr>
<td>ASTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$18.5</td>
<td>$15.9</td>
<td>$18.29</td>
<td>$30.00</td>
<td>$109.0K</td>
<td style="text-align: right;">88</td>
<td>60</td>
</tr>
<tr>
<td>ASTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.6</td>
<td>$5.5</td>
<td>$5.53</td>
<td>$22.50</td>
<td>$82.9K</td>
<td style="text-align: right;">128</td>
<td>233</td>
</tr>
<tr>
<td>ASTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$22.50</td>
<td>$82.5K</td>
<td style="text-align: right;">128</td>
<td>256</td>
</tr>
</tbody>
</table>

<h3>About AST SpaceMobile</h3>
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers and finally bringing broadband to the billions who remain unconnected. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
After a thorough review of the options trading surrounding AST SpaceMobile, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of AST SpaceMobile</h3>
<ul>
<li>Currently trading with a volume of 4,693,679, the ASTS's price is down by -3.33%, now at $24.99. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 48 days.</li>
</ul>
<h3>What The Experts Say On AST SpaceMobile</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $49.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B. Riley Securities continues to hold a Buy rating for AST SpaceMobile, targeting a price of $36. 
&#x2A; An analyst from Deutsche Bank persists with their Buy rating on AST SpaceMobile, maintaining a target price of $63. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AST SpaceMobile, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

ASTS

Decoding AST SpaceMobile's Options Activity: What's the Big Picture?

Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) revealed 12 unusual trades.
Delving into the details, we found 16% of traders were bullish, while 58% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $445,523, and 2 were calls, valued at $67,950.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $750.0 and $1170.0 for Regeneron Pharmaceuticals, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale activity within a strike price range from $750.0 to $1170.0 in the last 30 days. 
<h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727279127_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$30.7</td>
<td>$26.7</td>
<td>$30.7</td>
<td>$1040.00</td>
<td>$122.8K</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">41</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$46.5</td>
<td>$41.0</td>
<td>$44.6</td>
<td>$1000.00</td>
<td>$44.6K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$144.0</td>
<td>$137.5</td>
<td>$139.66</td>
<td>$1170.00</td>
<td>$41.8K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$97.0</td>
<td>$96.9</td>
<td>$97.0</td>
<td>$1120.00</td>
<td>$38.8K</td>
<td style="text-align: right;">89</td>
<td style="text-align: right;">25</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$100.7</td>
<td>$94.6</td>
<td>$96.6</td>
<td>$1120.00</td>
<td>$38.6K</td>
<td style="text-align: right;">89</td>
<td style="text-align: right;">29</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Following our analysis of the options activities associated with Regeneron Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Current Position of Regeneron Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 389,940, the REGN's price is down by -1.07%, now at $1034.78. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 36 days.</li>
</ul>
<h3>Expert Opinions on Regeneron Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $1184.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $1282. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $1015. 
&#x2A; An analyst from Leerink Partners downgraded its action to Market Perform with a price target of $1077. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $1250. 
&#x2A; In a cautious move, an analyst from BMO Capital downgraded its rating to Outperform, setting a price target of $1300. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

REGN

A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics

Barclays analyst Michael Leithead maintains Kronos Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRO#NYSE">KRO</a>) with a Underweight and raises the price target from $9 to $10.

Barclays Maintains Underweight on Kronos Worldwide, Raises Price Target to $10

Macro Notification

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Biden Says An All-Out War Is Possible In Middle East, But There Also Is Possibility Of A Settlement; There Needs To Be A Two-State Solution For Israel-Palestine

Sequoia Fund Q2 2024 Shareholder Letter

Liberty Broadband Corporation (LBRDK) Q2 2024 Earnings Call Transcript

Liberty Broadband Perp PFD A declares $0.4375 dividend

Tracking Ruane, Cunniff, & Goldfarb's Portfolio - Q2 2024 Update

Be Quick To Buy This Rare Over 7% Yielding Liberty Broadband Preferred

Tracking George Soros's 13F Portfolio - Q2 2024 Update

Fidelity Select Communication Services Portfolio Q2 2024 Review

Liberty Broadband sends merger deal counterproposal to Charter Communications

The Charter And Liberty Broadband Merger Negotiation Explained

Liberty Broadband-Charter deal will simplify structure, clean up complexity - analysts

AAPL

ARMK

ASHTF

ATUS

AXNX

AZNCF

BABA

BABAF

BKNG

CACC

CBOE

CFLT

CHTR

CMCSA

CNSWF

COST

ERFSF

FBCG

FBCV

FBND

FBTC

FCLD

FCOM

FCOR

FCPI

FDHY

FDIG

FDIS

FDLO

FDMO

FDRR

FDVV

FENY

FETH

FHLC

FIDI

FIDU

FMAG

FMAT

FMET

FNCL

FQAL

FREL

FSMD

FSTA

FTEC

FUTY

FVAL

FWONA

FWONB

FWONK

GOOG

GOOGL

JDCMF

LBRDA

LBRDB

LBRDK

LBRDP

LLYVA

LLYVB

LLYVK

LMGIF

NONOF

OKTA

ONEQ

RIVN

RLLCF

RYCEF

RYCEY

SCHW

SRCL

TSMWF

UMGNF

UNVGY

Press Releases

Liberty Broadband Corporation to Hold Virtual Annual Meeting of Stockholders

Liberty Broadband Corporation Declares Quarterly Cash Dividend on Series A Cumulative Redeemable Preferred Stock

Liberty Broadband Corporation Announces Proposed Private Offering of Exchangeable Senior Debentures

Liberty Broadband Corporation Prices Upsized Private Offering of $800 Million of 3.125% Exchangeable Senior Debentures due 2054

Liberty Broadband Corporation Closes Private Offering of $860 Million of 3.125% Exchangeable Senior Debentures Due 2054

Liberty Broadband Corporation Announces Second Quarter Earnings Release and Conference Call

Liberty Broadband Reports Second Quarter 2024 Financial Results

Liberty Broadband Corporation to Present at Goldman Sachs Communacopia & Technology Conference

Liberty Broadband Submits Counterproposal to Charter for Proposed Business Combination

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Liberty Broadband

Liberty Broadband (LBRDP) Forecast

Liberty Broadband (NASDAQ:LBRDP) Stock, Quote.Headers.trade-ideas